Steglatro, with the active ingredient ertugliflozin, is an oral medication used in the management of type 2 diabetes mellitus. It belongs to a class of drugs known as sodium-glucose cotransporter 2 (SGLT2) inhibitors, which work by helping the kidneys remove glucose from the bloodstream through the urine, thereby lowering blood sugar levels. Steglatro is typically prescribed alongside diet and exercise to improve glycemic control in adults with type 2 diabetes. It is not recommended for use in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. As with any medication, it is important to use Steglatro under the guidance of a healthcare professional to ensure its safe and effective use.